O Brien Greene & Co. Inc Sells 2,571 Shares of Johnson & Johnson (NYSE:JNJ)

O Brien Greene & Co. Inc lowered its position in Johnson & Johnson (NYSE:JNJ) by 26.9% in the third quarter, HoldingsChannel.com reports. The fund owned 6,996 shares of the company’s stock after selling 2,571 shares during the quarter. O Brien Greene & Co. Inc’s holdings in Johnson & Johnson were worth $1,134,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Occidental Asset Management LLC boosted its holdings in shares of Johnson & Johnson by 21.6% during the 2nd quarter. Occidental Asset Management LLC now owns 3,416 shares of the company’s stock worth $499,000 after buying an additional 607 shares during the period. Bangor Savings Bank raised its stake in Johnson & Johnson by 3.0% in the 2nd quarter. Bangor Savings Bank now owns 26,933 shares of the company’s stock worth $3,936,000 after purchasing an additional 776 shares in the last quarter. Voisard Asset Management Group Inc. grew its position in shares of Johnson & Johnson by 93.2% during the 2nd quarter. Voisard Asset Management Group Inc. now owns 1,244 shares of the company’s stock worth $182,000 after purchasing an additional 600 shares in the last quarter. JFS Wealth Advisors LLC raised its position in shares of Johnson & Johnson by 29.6% in the second quarter. JFS Wealth Advisors LLC now owns 20,461 shares of the company’s stock valued at $2,991,000 after buying an additional 4,671 shares in the last quarter. Finally, Brendel Financial Advisors LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $857,000. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Wolfe Research initiated coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Citigroup upped their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Wells Fargo & Company raised their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.67.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $149.31 on Monday. The firm has a market cap of $359.48 billion, a PE ratio of 21.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.51. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The firm’s fifty day moving average is $158.09 and its 200-day moving average is $156.40. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.66 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.